$CGC, $TLRY, $CRON, $ACB, $HEXO, $APHA

Marijuana is still illegal within US borders on a federal level, but with Canada legalizing it in October of 2018, many believe that the United States will follow in the near future.

The notion is that President Trump will not move to legalize it anytime soon if at all. And with this speculation, Short sellers have room to play with whether prices may be overly inflated.

The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks increased.

Short interest in Canopy Growth Corp. (NYSE:CGC) decreased slightly to 33.88-M shares from the prior 34.39-M. The stock trades within a 52-wk range of 24.39 – 59.25.

Tilray Inc. (NASDAQ:TLRY) short interest dropped to 6.25-M shares from the previous 6.71-M. Shares trade in a 52-wk range of 27.83 – 300.00.

Cronos Group Inc. (NASDAQ: CRON) shares short increased to 38.15-M from 35.93-M in the prior frame. Its shares trade in a 52-wk range of 6.50 – 25.10.

Aurora Cannabis Inc. (NYSE:ACB) saw its short interest increase to 116.51-M shares from 107.50-M in the prior frame. The 52-wk range is 4.58 – 12.52.

Hexo Corp.’s (NYSE:HEXO) short interest rose to 26.75-M shares from the previous 26.12-M. The 52-wk range is 3.73 – 8.40.

Short interest in Aphria Inc. (NYSE:APHA) increased to 29.28-M from the prior 27.41-M. The stock trades in a 52-wk range of 3.75 – 16.86.

Stay tuned…

  ACB, apha, CGC, CRON, HEXO, interest, investors, legalize, market, president, shore, short, speculation, TLRY, trade, traders, Trump

The following two tabs change content below.

• Bio
• Latest Posts

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Latest posts by Paul Ebeling (see all)

• Wall Street’s Key Stock Analysts Research Reports - January 24, 2020
• 2020: Energy Drinks, the Health Problems from the Beverages that Promise a Buzz - January 24, 2020
• 2020: Ferrari’ (NYSE:RACE) Portofino, an Everyday Supercar - January 24, 2020